相关实验视频

Updated: May 29, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

在牛皮患者的临床实践中比较阿达利穆马布生物仿制药

Domenico Giordano¹, Antonio Di Guardo², Annamaria Larosa³

¹Department of Dermatology, Sant'Andrea Hospital, Sapienza University, Rome, Italy.

Italian journal of dermatology and venereology

|February 3, 2025

概括

伊达西奥在减少牛皮的严重程度方面显示出比Imraldi更大的疗效,尽管在现实环境中,这两种阿达利穆马布生物仿制药都显示出可比的安全性和疗效.

科学领域:

皮肤病学皮肤病学
药理学药理学是指药理学的学科.
免疫学免疫学免疫学

背景情况:

生物药物,包括像Imraldi和Idacio这样的Adalimumab生物类似药,已经改变了牛皮的治疗方法.
生物类似药提供了具有成本效益的替代品,改善了全球获得慢性炎症疾病先进疗法的机会.
阿达利穆马布向TNF-alpha等细胞因子,这些细胞因子在炎症途径中至关重要.

研究的目的:

在中度至重度牛皮的患者中,比较两个阿达利穆马布生物类似药物Imraldi和Idacio的真实世界疗效和安全性.
评估以前用其他生物或全身疗法治疗的患者的治疗结果.

主要方法:

研究了一组32名牛皮患者,这些患者先前接受过生物药物或全身疗法治疗.
15名患者接受了Imraldi,其余患者接受了Idacio.
在24周内使用牛皮区域和严重程度指数 (PASI),视觉模拟量表 (PVAS),视觉模拟量表 (VAS),皮肤病生命质量指数 (DLQI) 和牛皮全球评估 (PGA) 评估有效性.

主要成果:

与Imraldi相比,Idacio在PASI,PVAS,VAS,DLQI和PGA得分方面表现出更大的降低.
伊姆拉尔迪和伊达西奥的安全性表现相似.
该研究观察到,在接受两种生物类似药的患者中,疾病严重程度和生活质量显著改善.

结论:

伊达西奥和伊姆拉尔迪是适度至重症牛皮的有效和安全治疗选择.
与Imraldi相比,Idacio在减少疾病严重程度指标方面表现出更好的疗效.
建议对更大的患者队伍进行进一步的研究,以探索个体治疗反应.

更多相关视频

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

相关概念视频

Bioequivalence: Overview

Bioequivalence: Overview

Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...